What question did this study set out to answer?

This research aims to evaluate the effectiveness of radium-223 in increasing overall survival for patients with metastatic prostate cancer.

July 17, 2013

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Key Points

This research aims to evaluate the effectiveness of radium-223 in increasing overall survival for patients with metastatic prostate cancer.
Randomized clinical trial terminated at interim analysis for efficacy.
Evaluated impact on overall survival amongst participants with metastatic prostate cancer.
ClinicalTrials.gov number NCT00699751 listed for reference.
Radium-223 significantly improved overall survival compared to control, confirming its beneficial role.
Results highlight its potential as an effective treatment for patients with metastatic prostate cancer.

Abstract

In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).

Demander à l'IA

Bookmark